US charges Cassava Sciences, two former executives for …
WEB13 hours ago · The U.S. Securities and Exchange Commission said on Thursday that it charged Cassava Sciences and two of the company's former executives for misleading claims about the results of Alzheimer’s ...
Cassava to Pay $40 Million to SEC Over Alzheimer’s Drug Claims
WEB10 hours ago · September 26, 2024 at 7:11PM EDT. (Bloomberg) -- Drugmaker Cassava Sciences Inc. and two former executives agreed to pay more than $40 million to resolve US Securities and Exchange Commission claims they misled the public about the success of an Alzheimer’s drug trial. Cassava published results in 2020 based on hand-selected data …
SEC Charges Cassava Sciences, Two Former Executives for …
WEB1 day ago · The Securities and Exchange Commission today announced Cassava Sciences, Inc., its founder and former CEO, Remi Barbier, and its former Senior Vice President of Neuroscience, Dr. Lindsay Burns, will pay more than $40 million to settle charges related to misleading statements made in September 2020 about the results of …
Cassava Sciences Resolves SEC Investigation
WEB1 day ago · AUSTIN, Texas, Sept. 26, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (“Cassava” or the “Company”) (Nasdaq: SAVA), a biotechnology company focused on Alzheimer’s disease, today announced that it has reached a settlement with the U.S. Securities and Exchange Commission (“SEC”) of negligence-based disclosure charges …
Cassava Sciences Resolves SEC Investigation - Yahoo Finance
WEB13 hours ago · AUSTIN, Texas, Sept. 26, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (“Cassava” or the “Company”) (Nasdaq: SAVA), a biotechnology company focused on Alzheimer’s disease, today ...
Cassava Sciences Resolves SEC Investigation - GlobeNewswire
WEB13 hours ago · Follow. AUSTIN, Texas, Sept. 26, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (“Cassava” or the “Company”) (Nasdaq: SAVA), a biotechnology company focused on Alzheimer’s disease ...
Cassava Sciences and former execs agree to SEC fines | STAT
WEB11 hours ago · Sept. 26, 2024. West Coast Biotech & Life Sciences Reporter. Facing charges from the Securities and Exchange Commission for misleading claims related to a controversial Alzheimer’s drug ...
Cassava Sciences settles SEC charges of ‘misleading
WEB12 hours ago · Shares of Cassava Sciences Inc. dropped more than 10% in the extended session Thursday after announcing a settlement with U.S. securities regulators, who had charged the pharma company and two ...
US charges Cassava Sciences, two former executives for ... - Yahoo
WEB13 hours ago · The U.S. Securities and Exchange Commission said on Thursday that it charged Cassava Sciences and two of the company's former executives for misleading claims about the results of Alzheimer's ...
Cassava Sciences Shares Fall After SEC Charges for ... - U.S. News
WEB1 day ago · The SEC said Cassava will pay $40 million to settle the civil charges, while Remi Barbier, the company's founder and former CEO, and Lindsay Burns, its former senior vice president of neuroscience ...
- Some results have been removed
Skip to content